Skip to main content
. 2021 Apr 23;29(5):446–455. doi: 10.1016/j.jsps.2021.04.007

Fig. 3.

Fig. 3

. Viability, chemotherapy-sensitization, and stability analysis of NL-miR-1296. (A) MDA-MB-231 viability after treatment with different concentrations (0.12–3 μM) of NL-miR-1296, or NL-miR-NC (B) Cells transfected using Lipofectamine. (C) Safety of nanoliposomes was analyzed using different n/p ratios (D) NL-miR-1296 sensitizes MDA-MB-231 to cisplatin treatment at a dose of as low as 1 μM. (E) A dose–response curve of cisplatin treatment in MDA-MB-231 cells (D) Down-expression of CCND1, and PARP1 in NL-miR-1296 treated MDA-MB-231 cells.